The ACCORD-2 Phase 3 trial conducted by Axsome Therapeutics has marked a significant milestone in the treatment of Alzheimer’s disease agitation. The trial successfully achieved its primary endpoint, demonstrating a statistically significant improvement in the time to relapse compared to placebo, with a p-value of 0.001. Additionally, the trial met its key secondary endpoint, showing a significant advantage in the prevention of relapse of Alzheimer’s disease agitation over placebo, also with a p-value of 0.001.
These results underscore the potential of the treatment being tested to offer a new therapeutic option for patients suffering from Alzheimer’s disease agitation, a condition that significantly impacts the quality of life for patients and their caregivers. The successful completion of this Phase 3 trial represents a crucial step forward in addressing the unmet medical needs in the management of Alzheimer’s disease agitation.
